Palisade Bio (PALI) Income from Continuing Operations (2010 - 2026)
Palisade Bio (PALI) posted quarterly Income from Continuing Operations of 10749000.0 for Q1 2026, down 365.12% year-over-year from 4054339.64 in Q1 2025, and down 7.64% quarter-over-quarter from 9986000.0 in Q4 2025.
Powered by 
Analysis
Palisade Bio (PALI) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Income from Continuing Operations for 17 consecutive years, with 10749000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 365.12% year-over-year to 10749000.0; the TTM figure through Mar 2026 stood at 26507000.0 (down 96.09% YoY), while the FY2025 annual figure was 45342000.0, up 4.19% from the prior year.
- Income from Continuing Operations retreated to 10749000.0 in Q1 2026 per PALI's latest filing, from 9986000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2311000.0 in Q1 2025 and bottomed at 38173000.0 in Q1 2023.
- Historically, Income from Continuing Operations has averaged 6374705.88 across 5 years, with a median of 3686000.0 in 2024.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 871.08% — and 2024, when it surged 90.34%.
- Palisade Bio's Income from Continuing Operations stood at 3850000.0 in 2022, then increased by 17.97% to 3158000.0 in 2023, then slipped by 7.28% to 3388000.0 in 2024, then slumped by 194.75% to 9986000.0 in 2025, then decreased by 7.64% to 10749000.0 in 2026.
- Business Quant data shows PALI's Income from Continuing Operations at 10749000.0 in Q1 2026, 9986000.0 in Q4 2025, and 2927000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Palisade Bio | 440.73 Mn | 315.53 Mn | - | -11.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.70 Mn |
| Mar 31, 2026 | -10.75 Mn |
| Dec 31, 2025 | -9.98 Mn |
| Sep 30, 2025 | -2.93 Mn |
| Jun 30, 2025 | -2.85 Mn |
| Mar 31, 2025 | -2.31 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Sep 30, 2024 | -3.60 Mn |
| Jun 30, 2024 | -4.21 Mn |
| Mar 31, 2024 | -3.67 Mn |
| Dec 31, 2023 | -3.16 Mn |
| Sep 30, 2023 | -3.79 Mn |
| Jun 30, 2023 | -3.61 Mn |
| Mar 31, 2023 | -2.53 Mn |
| Dec 31, 2022 | -3.85 Mn |
| Sep 30, 2022 | -4.42 Mn |
| Jun 30, 2022 | -3.58 Mn |
| Mar 31, 2022 | -3.89 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | -3.04 Mn |